Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
Last trade$1.42
Day change-$0.11 (-7.19%)
Day range$1.41 – $1.55
Volume430,083
Market cap$88M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$87.93M
Price / earnings
—
Price / book
1×
Price / sales
—
EV / sales
—
EV / EBITDA
-1.6×
Profitability
Earnings per share
-$0.77
Return on assets
-38.13%
Return on equity
-50.03%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
6.92×
Quick ratio
6.92×
Cash ratio
0.98×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$33.33M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for BDTX, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$70M
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$70M
$0
Selling, general and administrative
$5.15M
$4.66M
$4.26M
$3.97M
$3.54M
$4.1M
$4.96M
$5.98M
Research and development
$6.97M
$7.39M
$7M
$6.3M
$7.44M
$9.32M
$10.51M
$12.3M
Total operating expenses
$12.12M
$12.06M
$11.26M
$17.61M
$10.98M
$13.42M
$15.47M
$18.28M
Operating income
-$12.12M
-$12.06M
-$11.26M
-$17.61M
-$10.98M
-$13.42M
$54.53M
-$18.28M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$10.01M
-$9.91M
-$9.04M
-$15.12M
-$8.5M
-$10.56M
$56.54M
-$15.99M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$10.01M
-$9.91M
-$9.04M
-$15.12M
-$8.5M
-$10.56M
$56.54M
-$15.99M
Net income attributable to common shareholders
-$10.01M
-$9.91M
-$9.04M
-$15.12M
-$8.5M
-$10.56M
$56.54M
-$15.99M
EBITDA
-$12.09M
-$12.03M
-$11.23M
-$10.2M
-$10.89M
-$13.33M
$54.62M
-$18.19M
Basic earnings per share
-$0.17
-$0.17
-$0.16
-$0.26
-$0.15
-$0.19
$1.00
-$0.28
Diluted earnings per share
-$0.17
-$0.17
-$0.16
-$0.26
-$0.15
-$0.19
$0.98
-$0.28
Recent news
Company coverage with links to the original publishers.
Black Diamond Therapeutics (BDTX) stock climbed on Tuesday following the announcement of encouraging Phase 2 data for silevertinib in frontline non-small cell lung cancer patients with EGFR non-classical mutations. The company beat Q1 earnings estimates with a loss of 16 cents per share versus expected 18 cents, and holds $118.3 million in cash expected to fund operations into H2 2028. However, technical analysis shows mixed signals with the stock trading below both 20-day and 50-day moving averages, and a death cross pattern suggesting longer-term bearish sentiment.
Black Diamond Therapeutics announced positive Phase 2 results for silevertinib, its brain-penetrant EGFR inhibitor, in frontline NSCLC patients with EGFR non-classical mutations. The trial showed a preliminary median progression-free survival of 15.2 months, 60% overall response rate, and robust CNS activity with 86% CNS objective response rate. The company's CEO will present at the Jefferies Global Healthcare Conference on June 3, 2026.
Black Diamond Therapeutics reported a narrower net loss in Q2 2025, with improved operational efficiency and focus on silevertinib clinical development. The company completed Phase 2 trial enrollment and maintains a cash runway through Q4 2027.
Clarus reported Q2 2025 earnings with mixed results, narrowly beating analyst expectations on revenue and adjusted net loss per share, but experiencing revenue decline and ongoing profitability challenges.
Servier and Black Diamond Therapeutics have announced a global licensing agreement for BDTX-4933, a targeted oncology therapy in Phase 1 development. Servier will lead the development and commercialization of the therapy, with Black Diamond receiving an upfront payment and potential milestone and royalty payments.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.